Significant disparities exist in the diagnosis and treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer, according to Dr. Wei Zhang (above) of the Massachusetts General Hospital Cancer Center. Zhang’s research highlights the underrepresentation of racial and ethnic minorities, particularly Black and Hispanic patients, in HCC clinical trials and the lack of diversity among treating physicians.
“We see a lot of disparities, especially in the treatment of more advanced stage HCC,” Zhang said in an interview with HCPlive. “Black and Hispanic patients tend to be diagnosed at later stages and have lower rates of receiving potentially curative treatments like liver transplantation.”
Zhang emphasized the need for increased diversity in clinical trials to ensure treatments are effective across all populations. Currently, white patients are overrepresented while other racial and ethnic groups are underrepresented compared to their proportion of HCC cases.
Improving access to screening and early diagnosis is also crucial, as Black, Hispanic, and Asian patients are more likely to be diagnosed with advanced stage HCC. Zhang called for more education and outreach to underserved communities.
“Recognizing these disparities is the first step,” Zhang said. “We need a multi-pronged approach to really move the needle and improve outcomes for all patients with liver cancer.”
See “Recognizing Disparities in Hepatocellular Carcinoma Diagnosis, Care” (May 19, 2024)
